Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00469)
Name
Nilutamide
Synonyms    Click to Show/Hide the Synonyms of This API
nilutamide; 63612-50-0; Anandron; Nilandron; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione; Nilutamida; Nilutamidum; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione; RU-23908; RU 23908; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; Nilandrone; UNII-51G6I8B902; Nilandron;RU 23908; CHEMBL1274; CHEBI:7573; Nilutamidum [Latin]; Nilutamida [Spanish]; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; MFCD00864670; 51G6I8B902; NCGC00015754-08; CAS-63612-50-0; 2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-; DSSTox_CID_14165; DSSTox_RID_79118; DSSTox_GSID_34165; Nilutamide [USAN:INN:BAN]; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)-phenyl)imidazolidine-2,4-dione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1,3-diazolidine-2,4-dione; Nilandron (TN); RU 23908-10; SR-01000076034; Nilutamide (USAN/INN); BRN 0841906; Nilutamide, solid; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; PubChem19359; Spectrum_001625; Tocris-1759; SpecPlus_000902; Prestwick0_000928; Prestwick1_000928; Prestwick2_000928; Prestwick3_000928; Spectrum2_001973; Spectrum3_001633; Spectrum4_000600; Spectrum5_001512; Lopac-N-8534; N 8534; 2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-; BIDD:PXR0177; Lopac0_000879; SCHEMBL12670; BSPBio_000836; BSPBio_003325; KBioGR_001100; KBioSS_002105; MLS002154066; BIDD:GT0683; DivK1c_006998; SPECTRUM1504152; SPBio_002125; SPBio_003015; BPBio1_000920; GTPL2864; DTXSID3034165; KBio1_001942; KBio2_002105; KBio2_004673; KBio2_007241; KBio3_002545; BCPP000148; HMS1570J18; HMS1922F03; HMS2093A10; HMS2097J18; HMS2230E03; HMS3262P19; HMS3268C18; HMS3369I02; HMS3414N15; HMS3678N13; HMS3714J18; Pharmakon1600-01504152; BCP26617; ZINC3874498; Tox21 110213; Tox21_110213; Tox21_301589; Tox21_500879; ANW-58327; BDBM50135912; CCG-39427; NSC758683; SBB067297; STK633161; AKOS005565152; AKOS025147305; Tox21_110213_1; AC-5260; BCP9000990; DB00665; LP00879; MCULE-3215206804; NSC-758683; SB19036; SDCCGSBI-0050854.P004; NCGC00015754-01; NCGC00015754-02; NCGC00015754-03; NCGC00015754-04; NCGC00015754-05; NCGC00015754-06; NCGC00015754-07; NCGC00015754-09; NCGC00015754-10; NCGC00015754-11; NCGC00015754-12; NCGC00015754-15; NCGC00015754-16; NCGC00015754-22; NCGC00025280-01; NCGC00025280-02; NCGC00025280-03; NCGC00025280-04; NCGC00025280-05; NCGC00025280-06; NCGC00025280-07; NCGC00025280-08; NCGC00255271-01; NCGC00261564-01; AK-82300; AS-14123; HY-13702; SMR001233381; ST075550; SBI-0050854.P003; AB0013969; AB00053180; CS-0007719; EU-0100879; FT-0630740; C08164; D00965; AB00053180_07; 612N500; A834440; L000759; Q3877030; RU-23908;RU 23908;RU23908; SR-01000076034-1; SR-01000076034-3; SR-01000076034-5; SR-01000076034-6; SR-01000076034-9; BRD-K23566484-001-05-2; BRD-K23566484-001-09-4; Z2417927201; Nilutamide, European Pharmacopoeia (EP) Reference Standard; 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3'-trifluoromethyl-4'-nitrophenyl)4,4-dimethyl-imidazoline-2,5-dione; 1-(3'-trifluoromethyl-4'nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3'trifluoromethyl-4'-nitropheyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-'trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl imidazolidine-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazolidine-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-trifluoromethyl-4-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 3-(3-(trifluoromethyl)-4-nitrophenyl)-5,5-dimethylimidazolidine-2,4-dione; 5,5-Dimethyl-3-(4-nitro-3-trifluoromethyl-phenyl)-imidazolidine-2,4-dione; diethyl1,4-dihydro-2,6-dimethyl-1,4-diphenyl-3,5-pyridinedicarboxylate; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-imidazolidine-2,4-dione
Clinical Status
Approved
Disease Indication Prostate cancer ICD-11: 2C82 [1]
PubChem CID
4493
Formula
C12H10F3N3O4
Canonical SMILES
CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
InChI
1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
InChIKey
XWXYUMMDTVBTOU-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4493"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 317.22 Topological Polar Surface Area 95.2
XlogP 2 Complexity 515
Heavy Atom Count 22 Rotatable Bond Count 1
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Full List of Drug Formulations (DFMs) Containing This API
          Nilutamide 150 mg tablet Click to Show/Hide the Full List of Formulation(s):          3 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Docusate sodium; Magnesium stearate; Talc; Povidone; Starch, corn
                   Dosage Form Oral Tablet
                   Company Sanofi-Aventis
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Docusate sodium DIG Info Solute carrier SLCO2B1 (Ki = 2.3 uM) [2]
Povidone DIG Info Cholesterol 25-hydroxylase (IC50 = 78.3 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose; Docusate sodium; Magnesium stearate; Talc; Povidones; Starch, corn
                   Dosage Form Oral Tablet
                   Company Concordia Pharmaceuticals; Covis Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Docusate sodium DIG Info Solute carrier SLCO2B1 (Ki = 2.3 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Docusate sodium; Calcium stearate; Talc; Povidone k30; Starch, corn
                   Dosage Form Oral Tablet
                   Company ANI Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Docusate sodium DIG Info Solute carrier SLCO2B1 (Ki = 2.3 uM) [2]
References
1 FDA label for approved nilutamide from the official website of the U.S. Food and Drug Administration.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
4 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.